title: Adjuvant Therapy of Uveal Melanoma: Current Status.
abstract: The survival of patients with uveal melanoma remains poor because of the development of metastatic disease. Adjuvant therapy after treatment of the primary tumor has been tested but has not been shown to prevent the development of metastasis. Several new approaches are being developed. Cytotoxic and immunotherapeutic regimens are being more rationally applied using tumor genetic criteria to better identify patients at risk. Trials in the adjuvant setting of novel immunotherapeutic and targeted agents active in the metastatic setting are being developed, as are approaches to promote cellular differentiation and dormancy. The rarity and biology of uveal melanoma present challenges. Participation in well-designed, scientifically sound clinical trials is critical.
authors.affiliation: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, N.C., Ohio, USA.
authors.forename: Pierre L
authors.initials: PL
authors.lastname: Triozzi
authors.affiliation: Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Arun D
authors.initials: AD
authors.lastname: Singh
keywords: Adjuvant therapy; Melanoma; Metastasis